Philippe

President & Chief Scientific Officer @Eukarÿs

Paris, FR
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jan 2012 — Present

President & Chief Scientific Officer @Eukarÿs

View department →

FR

Eukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for the development of novel cellular tools for the bioproduction of recombinant proteins and viruses.

EDUCATION

1996 — 1997

The Johns Hopkins University

Post-doc, Human/Medical Genetics

1993 — 1997

Université Paris Cité

PhD, Human Molecular Genetics

2001 — 2003

Paris-Sud University (Paris XI)

Master, Biostatistics

1980 — 1992

Université Paris VII, Faculté de Médecine Lariboisière-Saint Louis

MD, Medicine, Hepato-gastroenterology

1972 — 1979

Lycée Carnot, Paris

High School, College and high school

SKILLS

BiomarkersLife SciencesPharmacogeneticsDrug DiscoveryTranslational ResearchLifesciencesMolecular & Cellular BiologyTranslational MedicineMolecular GeneticsGene ExpressionClinical ResearchMolecular BiologyDnaC3p3 TechnologyBiotechnologyGeneticsDiabetesGenomicsClinical DevelopmentCell BiologyCellDrug DevelopmentIn VivoRna BiologyDna SequencingGenetic EngineeringGene Expression Profiling

ABOUT PHILIPPE

As a molecular geneticist and medical doctor by training, I serve as the scientific head of Eukarÿs, a French biotech company I founded. Eukarÿs has developed the first-ever artificial gene expression system, known as C3P3, capable of autonomously synthesizing messenger RNA (mRNA) and the corresponding protein of interest directly in vivo within mammalian and other eukaryotic cells.With the C3P3 system, our mission is to transform the manufacturing of innovative therapeutics by dramatically lowering production costs. We provide pharmaceutical companies, biotech firms, contract development and manufacturing organizations (CDMOs), and academic institutions with a comprehensive suite of C3P3-based tools for both research and industrial applications. These tools enable high-yield production of advanced protein-based therapeutics—including vaccines, viruses, and monoclonal antibodies—in mammalian cells.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.